Professor Park Jeong-je of Gyeongsang National University Hospital won the Best Association for Head and Neck Oncology
Dec 03, 2025
Gyeongsang National University Hospital (Hospital Director Ahn Sung-ki) announced that Professor Park Jeong-je of the Department of Otolaryngology received the 'Best Research Award' at the Fall Conference of the Korean Head and Neck Oncology Association on November 29.
At this conference, Professor Park Jung-je presented a study titled 'Sirt6 Suppresses Schwannoma Growth via ROS-Mediated Sirt1 Downregulation' and was honored with the Best Performance Award for being highly evaluated for its completeness and academic contribution.
The study identified what molecular biological mechanism Sirt6 protein is involved in the regulation of schwannoma growth, and in particular, it received the attention of the society by newly revealing the inhibition process of tumor growth, focusing on the ROS (active oxygen species)-mediated Sirt1 expression inhibition mechanism.
Here, schwannoma is a benign tumor that occurs in Schwann cells surrounding the nerve, and depending on the location, it can cause neurological dysfunction such as hearing loss and facial paralysis.
Sirt6 is a protein involved in cell aging and DNA damage repair, and is recently known to have tumor suppression and is also known to play an important role in controlling cell stress.
Sirt1 is a protein involved in cell survival and metabolic regulation and is known to be involved in signaling associated with tumor growth in some situations. In the present study, expression is inhibited by Sirt6, and it has been suggested as a key regulator of decreased tumor growth.
Professor Park Jung-je's research team suggested a new role of the Sirt6-Sirt1 pathway in the field of nervous system tumors with a high risk of nerve function damage and sequelae after surgery, and was recognized for its academic significance in that it can be used as important basic data for future research on treatment targets and prognostic factors.
Professor Park Jung-je said, "This award is very meaningful because the research team has recognized the achievements of tumor mechanism research that has been continuously carried out. We will continue to strengthen convergence research that connects clinical practice and foundation in the field of head and neck tumors and nervous system tumors and contribute substantially to patient treatment in the future."
At this conference, Professor Park Jung-je presented a study titled 'Sirt6 Suppresses Schwannoma Growth via ROS-Mediated Sirt1 Downregulation' and was honored with the Best Performance Award for being highly evaluated for its completeness and academic contribution.
The study identified what molecular biological mechanism Sirt6 protein is involved in the regulation of schwannoma growth, and in particular, it received the attention of the society by newly revealing the inhibition process of tumor growth, focusing on the ROS (active oxygen species)-mediated Sirt1 expression inhibition mechanism.
Here, schwannoma is a benign tumor that occurs in Schwann cells surrounding the nerve, and depending on the location, it can cause neurological dysfunction such as hearing loss and facial paralysis.
Sirt6 is a protein involved in cell aging and DNA damage repair, and is recently known to have tumor suppression and is also known to play an important role in controlling cell stress.
Sirt1 is a protein involved in cell survival and metabolic regulation and is known to be involved in signaling associated with tumor growth in some situations. In the present study, expression is inhibited by Sirt6, and it has been suggested as a key regulator of decreased tumor growth.
Professor Park Jung-je's research team suggested a new role of the Sirt6-Sirt1 pathway in the field of nervous system tumors with a high risk of nerve function damage and sequelae after surgery, and was recognized for its academic significance in that it can be used as important basic data for future research on treatment targets and prognostic factors.
Professor Park Jung-je said, "This award is very meaningful because the research team has recognized the achievements of tumor mechanism research that has been continuously carried out. We will continue to strengthen convergence research that connects clinical practice and foundation in the field of head and neck tumors and nervous system tumors and contribute substantially to patient treatment in the future."
|
This article was translated by Naver AI translator.
